>_ QFI Terminal
Terminal › Stocks › LIMN

Liminatus Pharma, Inc. Class A Common Stock (LIMN) Stock

Healthcare · Biotechnology · US
$0.14 -6.60%
Last updated Nov 12, 2026 10:46 UTC

LIMN Key Statistics

Market Cap$3.76M
P/E (TTM)-0.05
P/S (TTM)—
P/B (TTM)-0.34
Revenue (TTM)$0.00
EPS (TTM)$-2.91
Dividend Yield—
ROE (TTM)194.96%
Net Margin0.00%
Gross Margin0.00%
52W High$17.92
52W Low$4.75
Analyst View—
Price Target—
Employees3
Volume4,993,497

About Liminatus Pharma, Inc. Class A Common Stock

Liminatus Pharma, Inc. operates as a clinical-stage immuno-oncology company that develops novel cancer therapies. The company is based in LA Palma, California.

CEO: Chris Kim. Company website

LIMN — Frequently Asked Questions

What is the LIMN stock price today?

Liminatus Pharma, Inc. Class A Common Stock (LIMN) trades at $0.14, down 6.60% on the day, as of Nov 12, 2026 10:46 UTC.

What is Liminatus Pharma, Inc. Class A Common Stock's market cap?

Liminatus Pharma, Inc. Class A Common Stock has a market capitalisation of $3.76M, calculated from the live LIMN share price and shares outstanding.

What is the P/E ratio of LIMN?

LIMN has no meaningful price-to-earnings ratio: Liminatus Pharma, Inc. Class A Common Stock lost $2.91 per share over the last twelve months, and a P/E is only defined on positive earnings.

How much revenue does Liminatus Pharma, Inc. Class A Common Stock make?

Liminatus Pharma, Inc. Class A Common Stock generated revenue of $0.00 over the trailing twelve months.

What is the 52-week range for LIMN?

LIMN has traded between $4.75 and $17.92 over the past 52 weeks, and the last price is 99.2% below that high.

Is Liminatus Pharma, Inc. Class A Common Stock profitable?

Yes. Liminatus Pharma, Inc. Class A Common Stock keeps 0.00% of revenue as net income over the trailing twelve months.

What sector is Liminatus Pharma, Inc. Class A Common Stock in?

Liminatus Pharma, Inc. Class A Common Stock is classified under the Healthcare sector and the Biotechnology industry, and is domiciled in US .

Who is the CEO of Liminatus Pharma, Inc. Class A Common Stock?

Chris Kim is the chief executive of Liminatus Pharma, Inc. Class A Common Stock, which employs 3 people.

Where can I track LIMN in real time?

QFI Terminal shows LIMN with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.

See LIMN live in QFI Terminal

Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.

Open LIMN in Terminal See plans

Biotechnology stocks

REGN Regeneron Pharmaceuticals, Inc. VRTX Vertex Pharmaceuticals Incorporated ONC BeOne Medicines AG INCY Incyte Corporation ALNY Alnylam Pharmaceuticals, Inc. JAZZ Jazz Pharmaceuticals plc ARGX argenx SE GMAB Genmab A/S NBIX Neurocrine Biosciences, Inc. BMRN BioMarin Pharmaceutical Inc. UTHR United Therapeutics Corporation CDT CDT Equity Inc. MRNA Moderna, Inc. EXEL Exelixis, Inc. BNTX BioNTech SE SRPT Sarepta Therapeutics, Inc. HALO Halozyme Therapeutics, Inc. INSM Insmed Incorporated MDGL Madrigal Pharmaceuticals, Inc. TECH Bio-Techne Corporation ASND Ascendis Pharma A/S CAI Caris Life Sciences, Inc. IONS Ionis Pharmaceuticals, Inc. BBIO BridgeBio Pharma, Inc.

More Healthcare stocks

UNH UnitedHealth Group Incorporated CVS CVS Health Corp. MCK McKesson Corporation COR Cencora, Inc. NVO Novo Nordisk A/S CI Cigna Corporation CAH Cardinal Health, Inc. CNC Centene Corp. ELV Elevance Health Inc. HUM Humana Inc. JNJ Johnson & Johnson LLY Eli Lilly and Company HCA HCA Healthcare, Inc. MRK Merck & Co., Inc. ABBV AbbVie Inc. PFE Pfizer Inc.